S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms

Wesentliche Neuerungen in der Leitlinie zur Diagnostik und Therapie des hepatozellulären Karzinoms

Die S3-Leitlinie „Diagnostik und Therapie des hepatozellulären Karzinoms und der biliären Karzinome“ umfasst 2 Tumorentitäten. Bisher besteht nur eine Leitlinie zur Diagnostik und Therapie des hepatozellulären Karzinoms (HCC). Daher wird in diesem Kapitel nur auf die Veränderungen der Leitlinie des hepatozellulären Karzinoms eingegangen.

Folgende wesentliche Änderungen ergeben sich zur S3-Leitlinie des hepatozellulären Karzinoms von 2013:

• Histopathologische und molekulare Diagnostik): Die Leberbiopsie wurde als wichtige diagnostische Maßnahme zur Diagnosestellung des hepatozellulären Karzinoms (in der zirrhotischen Leber) gestärkt. In der palliativen Situation sollte eine bioptische Sicherung erfolgen.

• Bildgebende Diagnostik: Bisher wurde in einer zirrhotischen Leber die Diagnose eines hepatozellulären Karzinoms ab 2 cm mittels zweier unabhängiger Bildgebungen (MRT, CT oder Ultraschall) bei typischem Kontrastverhalten gestellt. Die Empfehlung wurde dahingehend geändert, dass die Diagnose eines hepatozellulären Karzinoms in zirrhotischer Leber aufgrund eines typischen Kontrastmittelverhaltens mit arterieller Hypervaskularisation und Auswaschen in der portalvenösen und venösen Phase im kontrastverstärkten MRT diagnostiziert werden soll. Bei unklarem MRT-Befund sollten ein triphasisches CT und/oder ein kontrastverstärkter Ultraschall herangezogen werden.

• Chirurgische Therapieverfahren): Bei geeigneten Patienten mit einem HCC außerhalb der Mailand-Kriterien und innerhalb der UCSF-Kriterien kann eine Lebertransplantation erfolgen, insbesondere dann, wenn ein Downstaging bis innerhalb der Mailand-Kriterien gelingt. Zum Downstaging stehen, ebenso wie beim Bridging, mehrere Therapieverfahren (transarterielle Verfahren, ablative Verfahren und Leberresektion) zur Verfügung.

• Interventionelle Therapieverfahren):

  • Als Standardmethode der lokalablativen Verfahren war bisher nur die Radiofrequenzablation empfohlen. Aufgrund der inzwischen guten Datenlage für die Mikrowellenablation wurde diese als äquivalentes Verfahren aufgenommen.

  • Die transarterielle Chemoembolisation (TACE) sollte mehrfach durchgeführt werden, solange ein Ansprechen hierauf nachweisbar ist und behandelbare hypervaskularisierte Tumoranteile verbleiben.

  • Die Indikation zur Fortführung der TACE soll nach 2 Behandlungszyklen im Tumorboard überprüft werden.

  • Die transarterielle Radioembolisation (TARE) kann nach Beschluss des Tumorboards bei Patienten mit erhaltener Leberfunktion im intermediären HCC-Stadium anstelle einer TACE eingesetzt werden.

  • Eine Hochpräzisionsradiotherapie (Stereotactic Body Radiotherapy, SBRT) kann in Betracht gezogen werden, wenn andere lokale Therapieverfahren nicht möglich sind (z. B. hohe Wahrscheinlichkeit für ein Therapieversagen, eingeschränkte Leberfunktion, technische Hindernisse).

• Systemtherapie: Zum Zeitpunkt der letzten Leitlinie konnte nur Sorafenib evidenzbasiert empfohlen werden. Zwischenzeitlich sind mehrere weitere Substanzen hinzugekommen:

  • Die Kombinationstherapie Atezolizumab und Bevacizumab ist als Erstlinie zugelassen und in der Zulassungsstudie Sorafenib überlegen.

  • Als weitere Erstlinientherapie ist der Tyrosinkinase-Inhibitor Lenvatinib zugelassen.

  • Mehrere Tyrosinkinase-Inhibitoren und der VEGFR-R2-Antikörper Ramucirumab (bei AFP > 400 ng/ml) stehen als weitere zugelassene Therapieoptionen zur Verfügung.

Publication History

Article published online:
18 January 2022

• Literatur

• 1 Howick J. et al The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document). Available from: 2011 http://www.cebm.net/index.aspx?o=5653
• 2 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Ständige Kommission, L. AWMF-Regelwerk „Leitlinien“. 1. Auflage 2012 [cited 09.12.2013. Available from: http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html
• 3 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
• 4 http://gco.iarc.fr
• 5 http://krebsdaten.de
• 6 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
• 7 Sangiovanni A. et al The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310
• 8 Ioannou GN. et al Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945, 945.e1–e4
• 9 Kanwal F. et al Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology 2020; 71: 44-55
• 10 Kanwal F. et al Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155: 1828-1837.e2
• 11 EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
• 12 Frenette CT. et al A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019; 3: 302-310
• 13 Cucchetti A. et al Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 2013; 27: 961-972
• 14 Brouwer WP. et al Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat 2017; 24: 1023-1031
• 15 Papatheodoridis G. et al PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806
• 16 Papatheodoridis GV. et al Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356
• 17 Yuen MF. et al Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88
• 18 Yang HI. et al Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574
• 19 Wong VW. et al Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-1665
• 20 Yip TC. et al Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol 2020; 72: 847-854
• 21 Marrero JA. et al Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750
• 22 Mittal S. et al Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2016; 14: 124-131.e1
• 23 EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264
• 24 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156: 1264-1281.e4
• 25 Roeb E. et al [S2k Guideline non-alcoholic fatty liver disease]. Z Gastroenterol 2015; 53: 668-723
• 26 Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. Z Gastroenterol 2019; 57: 508-517
• 27 Angulo P. et al The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854
• 28 Tanwar S. et al Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017; 51: 268-277
• 29 Kanwal F. et al Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017; 153: 996-1005.e1
• 30 Masuzaki R. et al Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-1961
• 31 El-Serag HB. et al Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016; 64: 130-137
• 32 Ioannou GN. et al Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019; 157: 1264-1278.e4
• 33 Omata M. et al Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317-370
• 34 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD?. J Hepatol 2018; 68: 326-334
• 35 Simeone JC. et al Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017; 9: 679-688
• 36 Fujiwara N. et al Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018; 68: 526-549
• 37 Gellert-Kristensen H. et al Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology 2020; 72: 845-856
• 38 Lissing M. et al Primary liver cancer in acute hepatic porphyria: a national cohort study. Journal of Hepatology 2020; 73: S63
• 39 Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 (Suppl. 01) S63-S70
• 40 de Fost M. et al Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36: 53-58
• 41 Bartlett DC. et al Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 2014; 37: 745-752
• 42 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36: 1239-1251
• 43 Papatheodoridis GV. et al Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-967
• 44 Poon D. et al Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-1118
• 45 Chang MH. et al Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859
• 46 Indolfi G. et al Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4: 466-476
• 47 Inoue M. et al Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97: 293-300
• 48 Bravi F. et al Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017; 26: 368-377
• 49 Aleksandrova K. et al The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102: 1498-1508
• 50 Setiawan VW. et al Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148: 118-125 ; quiz e15
• 51 Saab S. et al Impact of coffee on liver diseases: a systematic review. Liver Int 2014; 34: 495-504
• 52 Bhurwal A. et al Inverse Association of Coffee with Liver Cancer Development: An Updated Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2020; 29: 421-428
• 53 Kennedy OJ. et al Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017; 7: e013739
• 54 Filippini T. et al Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2020; 3: Cd005004
• 55 Singh S. et al Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11 (12) 1573-1584.e1–e2 ; quiz e88–e89
• 56 Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int 2018; 38: 2018-2027
• 57 Cunha V. et al Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020; 19: 232-237
• 58 Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother 2013; 47: 1348-1352
• 59 Inzucchi SE. et al Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Jama 2014; 312: 2668-2675
• 60 Zhang X. et al Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60: 2008-2016
• 61 Vandenbulcke H. et al Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 2016; 65: 543-551
• 62 Ascha MS. et al The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978
• 63 EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154-181
• 64 Wang ZY. et al Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm – A retrospective cohort study. Am J Surg 2020; 219: 717-725
• 65 Jang JW. et al Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. Clin Infect Dis 2020; 71: 546-555
• 66 Yang Y. et al A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015; 35: 2147-2154
• 67 Cabibbo G. et al Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019; 71: 265-273
• 68 Dang H. et al Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020; 71: 1910-1922
• 69 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422
• 70 Trevisani F. et al Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102: 2448-2457 ; quiz 2458
• 71 Trevisani F. et al Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102: 2448-2457 ; quiz 2458
• 72 Pocha C. et al Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study. Aliment Pharmacol Ther 2013; 38: 303-312
• 73 Trinchet JC. et al Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
• 74 Tzartzeva K. et al Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718.e1
• 75 Song BG. et al Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018; 30: 1447-1452
• 76 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11: e1001624
• 77 Loomba R. et al AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020; 158: 1822-1830
• 78 Petrick JL. et al Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol 2018; 113: 1494-1505
• 79 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020; 69: 1343-1352
• 80 Singh S. et al Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1–e9 ; quiz e39–e40
• 81 Sterling RK. et al Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325
• 82 Taylor RS. et al Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 2020; 158: 1611-1625.e12
• 83 Rockey DC. et al Liver biopsy. Hepatology 2009; 49: 1017-1044
• 84 Silva MA. et al Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-1596
• 85 Müllhaupt B. et al Is tumor biopsy necessary?. Liver Transpl 2011; 17 (Suppl. 02) S14-S25
• 86 Fuks D. et al Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 2014; 610: 589-593
• 87 Paradis VFM, Park YN, Schirmacher P. Tumors of the liver and intrahepatic bile ducts. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. Lyon: International Agency for Research on Cancer; 2019: 215-264
• 88 Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-993
• 89 Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664
• 90 Burt AD. et al Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018; 73: 369-385
• 91 Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48900 necropsies. Cancer 1954; 7: 462-503
• 92 Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995; 76: 579-588
• 93 Di Tommaso L. et al Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725-734
• 94 Di Tommaso L. et al The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-754
• 95 Lee YJ. et al Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275: 97-109
• 96 Chen N. et al Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. Magn Reson Med Sci 2016; 15: 49-59
• 97 Granito A. et al Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013; 37: 355-363
• 98 Haradome H. et al Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34: 69-78
• 99 Inoue T. et al Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012; 47: 1036-1047
• 100 Maiwald B. et al Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?. PLoS One 2014; 9: e111935
• 101 Park VY. et al Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 2014; 34: 1593-1602
• 102 Sun HY. et al Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45: 96-103
• 103 Tsurusaki M. et al Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 2016; 51: 71-79
• 104 Burrel M. et al MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-1042
• 105 Di Martino M. et al Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 2013; 23: 887-896
• 106 Castilla-Lievre MA. et al Diagnostic value of combining (1)(1)C-choline and (1)(8)F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43: 852-859
• 107 Chotipanich C. et al Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT. Asian Pac J Cancer Prev 2016; 17: 3569-3573
• 108 Hong G. et al Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol 2016; 64: 852-859
• 109 Lin CY. et al Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med 2017; 42: e183-e187
• 110 Khalili K. et al Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728
• 111 Giorgio A. et al Contrast-Enhanced Ultrasound: a Simple and Effective Tool in Defining a Rapid Diagnostic Work-up for Small Nodules Detected in Cirrhotic Patients during Surveillance. J Gastrointestin Liver Dis 2016; 25: 205-211
• 112 Schellhaas B. et al Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol 2017; 29: 1036-1044
• 113 Mitchell DG. et al LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015; 61: 1056-1065
• 114 Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338
• 115 Chan AC. et al Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford) 2013; 15: 439-448
• 116 Chevret S. et al A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141
• 117 Johnson PJ. et al Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade. J Clin Oncol 2015; 33: 550-558
• 118 Kitai S. et al Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75 (Suppl. 01) 83-90
• 119 Leung TW. et al Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769
• 120 Marrero JA. et al Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-716
• 121 Pinato DJ. et al The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66: 338-346
• 122 Vitale A. et al Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc 2009; 41: 1260-1263
• 123 Yau T. et al Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-1700.e3
• 124 Sohn JH. et al Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol 2017; 15: 746-755.e4
• 125 Yang A. et al Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database. Oncotarget 2017; 8: 97428-97438
• 126 Krenzien F. et al Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals. J Gastrointest Surg 2018; 22: 840-848
• 127 Cherqui D. et al Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250: 738-746
• 128 Eguchi S. et al Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 552-557
• 129 Sapisochin G. et al The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016; 64: 2077-2088
• 130 Mazzaferro V, Battiston C, Sposito C. Pro (With Caution): Extended oncologic indications in liver transplantation. Liver Transpl 2018; 24: 98-103
• 131 Mazzaferro V. et al Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
• 132 Agopian VG. et al Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg 2017; 266: 525-535
• 133 Bundesärztekammer, Richtlinien zur Organtransplantation gem. § 16 TPG. Deutsches Ärzteblatt |.
• 134 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020; 26: 823-831
• 135 Yao FY. et al Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
• 136 Mazzaferro V. et al Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43
• 137 Sinha J. et al Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology 2019; 70: 1185-1196
• 138 Lai Q. et al Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020; 12: 452
• 139 Mehta N. et al Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018; 16: 955-964
• 140 Otto G. et al Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267
• 141 Di Sandro S. et al Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. J Am Coll Surg 2018; 226: 1147-1159
• 142 Ferrer-Fàbrega J. et al Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 2016; 63: 839-849
• 143 Scatton O. et al Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation. J Surg Oncol 2015; 111: 1007-1015
• 144 de Haas RJ. et al Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. Hepatology 2018; 67: 204-215
• 145 Bhangui P. et al Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?. Ann Surg 2016; 264: 155-163
• 146 Pichlmayr R. Is there a place for liver grafting for malignancy?. Transplant Proc 1988; 20 (Suppl. 01) 478-482
• 147 Roayaie S. et al Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540
• 148 Shetty K. et al Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-918
• 149 Lee HW. et al Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. Liver Transpl 2018; 24: 1243-1251
• 150 Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19: 634-645
• 151 Vibert E. et al Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137
• 152 Yao FY. et al Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968-1977
• 153 Hameed B. et al Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 200: 945-951
• 154 Heimbach JK. et al AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380
• 155 Mehta N. et al Alpha-Fetoprotein Decrease from > 1000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019; 69: 1193-1205
• 156 EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433-485
• 157 Martin P. et al Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144-1165
• 158 Adani GL. et al Elderly versus young liver transplant recipients: patient and graft survival. Transplant Proc 2009; 41: 1293-1294
• 159 Cross TJ. et al Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382-1388
• 160 Grąt M. et al Short and long-term outcomes after primary liver transplantation in elderly patients. Pol Przegl Chir 2013; 85: 581-588
• 161 Aduen JF. et al Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc 2009; 84: 973-978
• 162 Lipshutz GS. et al Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775-781 ; discussion 781–784
• 163 Oezcelik A. et al Living Donor Liver Transplantation in Patients 70 Years or Older. Transplantation 2015; 99: 1436-1440
• 164 Taner CB. et al Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years. Hepatol Int 2012; 6: 403-407
• 165 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 2017; 52: 143-149
• 166 Kulik L. et al Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67: 381-400
• 167 Sneiders D. et al Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation 2018; 102: 88-96
• 168 Clavien PA. et al Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22
• 169 Beal EW. et al Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front Oncol 2016; 6: 143
• 170 Cascales-Campos P. et al Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?. Transplant Proc 2018; 50: 591-594
• 171 Finkenstedt A. et al Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int 2016; 36: 688-695
• 172 Györi GP. et al Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017; 49: 236-243
• 173 Jianyong L. et al Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep 2017; 7: 41624
• 174 Nicolini D. et al Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017; 23: 3690-3701
• 175 Gabr A. et al Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol 2017; 93: 100-106
• 176 Lai Q. et al The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl 2019; 25: 1023-1033
• 177 Oligane HC, Xing M, Kim HS. Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 2017; 282: 869-879
• 178 Millonig G. et al Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279
• 179 Cucchetti A. et al Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344-1354
• 180 Lai Q. et al Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108-1118
• 181 Kim DJ. et al Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant 2014; 14: 1383-1390
• 182 Riaz A. et al Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. Jama 2010; 303: 1062-1069
• 183 O’Connor JK. et al Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012; 18: 949-954
• 184 Facciuto ME. et al Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 2012; 105: 692-698
• 185 Sapisochin G. et al Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017; 67: 92-99
• 186 Degroote H. et al Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2019; 33: 231-238
• 187 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21: 1142-1152
• 188 Chapman WC. et al Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg 2017; 224: 610-621
• 189 Graziadei I. et al Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016; 128: 679-690
• 190 Mazzaferro V. et al Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018; 154: 128-139
• 191 Halazun KJ. et al Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg 2018; 268: 690-699
• 192 Hong SK. et al Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. Hepatobiliary Surg Nutr 2016; 5: 453-460
• 193 Kornberg A, Schernhammer M, Friess H. (18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017; 5: 224-234
• 194 Assalino M. et al Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study. Transpl Int 2020; 33: 567-575
• 195 Parik ND, Yopp A, Singal AG. Controversies in criteria for liver transplantation in hepatocellular carcinoma. Curr Opin Gastroenterol 2016; 32: 182-188
• 196 Salem R. et al Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151: 1155-1163.e2
• 197 Ettorre GM. et al Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017; 41: 241-249
• 198 Schwacha-Eipper B. et al Immunotherapy as a downstaging therapy for liver transplantation. Hepatology 2020; 72: 1488-1490
• 199 Golse N. et al Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review. Exp Clin Transplant 2018; 16: 227-236
• 200 Hoffmann K. et al Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients – a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015; 15: 392
• 201 Berenguer M. et al Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104: 1143-1149
• 202 Verna EC. et al Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020; 20: 333-347
• 203 Vivarelli M. et al Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503
• 204 Vivarelli M. et al Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-628
• 205 Rodríguez-Perálvarez M. et al Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199
• 206 Decaens T. et al Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-7325
• 207 Tan PS. et al Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation. Transplantation 2019; 103: 470-480
• 208 Duvoux C, Toso C. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. Transplant Rev (Orlando) 2015; 29: 168-174
• 209 Tarantino G. et al Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016; 7: 387
• 210 Teperman L. et al Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013; 19: 675-689
• 211 De Simone P. et al Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269
• 212 Fischer L. et al Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation 2015; 99: 1455-1462
• 213 Geissler EK. et al Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016; 100: 116-125
• 214 Trevisani F. et al Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42: 341-347
• 215 Paradis V. et al Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859
• 216 Piscaglia F. et al Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838
• 217 Ertle J. et al Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443
• 218 Zhou Y. et al Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. Surg Oncol 2014; 23: 236-242
• 219 Faber W. et al Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery 2013; 153: 510-517
• 220 Cauchy F. et al Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 2013; 100: 113-121
• 221 Dasari BV. et al Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB (Oxford) 2020; 22: 383-390
• 222 Ju M, Yopp AC. The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?. Cancers (Basel) 2019; 11: 1441
• 223 Moris D. et al Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2018; 44: 927-938
• 224 Arnaoutakis DJ. et al Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014; 21: 147-154
• 225 Lang H. et al Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007; 205: 27-36
• 226 Bège T. et al Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series. J Gastrointest Surg 2007; 11: 619-625
• 227 Teegen EM. et al Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center. Int J Surg Oncol 2018; 2018: 4195076
• 228 Wang YY. et al Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma. J Surg Oncol 2018; 118: 440-445
• 229 Rubin TM. et al Kinetic validation of the LiMAx test during 10 000 intravenous (13)C-methacetin breath tests. J Breath Res 2017; 12: 016005
• 230 Stockmann M. et al Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009; 250: 119-125
• 231 Huang Z. et al Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A meta-analysis. PLoS One 2018; 13: e0190512
• 232 Simonetto DA, Liu M, Kamath PS. Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019; 94: 714-726
• 233 Roayaie S. et al The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015; 62: 440-451
• 234 Ishizawa T. et al Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916
• 235 Torzilli G. et al A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013; 257: 929-937
• 236 Koh YX. et al Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World J Hepatol 2018; 10: 433-447
• 237 Zaydfudim VM. et al Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016; 264: 650-658
• 238 Tsilimigras DI. et al Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020; 27: 2321-2331
• 239 Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7: 245-252
• 240 Feng X. et al A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence. HPB (Oxford) 2017; 19: 667-674
• 241 Wakabayashi G. et al Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 2015; 261: 619-629
• 242 Cherqui D, Soubrane O. Laparoscopic Liver Resection: An Ongoing Revolution. Ann Surg 2017; 265: 864-865
• 243 Andreou A. et al Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis. Surg Oncol 2018; 27: 751-758
• 244 Haber PK. et al Laparoscopic liver surgery in cirrhosis – Addressing lesions in posterosuperior segments. Surg Oncol 2019; 28: 140-144
• 245 Levi Sandri GB. et al Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Surg Endosc 2019; 33: 1451-1458
• 246 Felli E. et al Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience. Updates Surg 2015; 67: 215-222
• 247 Bruix J. et al Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-1354
• 248 Lee JH. et al Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148: 1383-1391.e6
• 249 Mazzaferro V. et al Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554
• 250 Samuel M. et al Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; 1: Cd001199
• 251 Takayama T. et al Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807
• 252 Chen MS. et al A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328
• 253 Feng K. et al A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794-802
• 254 Huang J. et al A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912
• 255 Ng KKC. et al Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104: 1775-1784
• 256 Yin L. et al Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61: 82-88
• 257 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
• 258 Wahab MA. et al Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med 2014; 46: 36-41
• 259 Ramacciato G. et al Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2006; 53: 898-903
• 260 Di Costanzo GG. et al Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30: 559-565
• 261 Cucchetti A. et al An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014; 46: 257-263
• 262 Nishikawa H. et al Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011; 11: 143
• 263 Uhlig J. et al Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 2019; 29: 2679-2689
• 264 Salmi A. et al Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis. J Ultrasound 2009; 12: 118-124
• 265 Mohanty S. et al Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma. J Surg Oncol 2016; 113: 175-180
• 266 Yamauchi R. et al Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis. Intern Med 2019; 58: 661-665
• 267 Livraghi T. et al Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-661
• 268 Lencioni RA. et al Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240
• 269 Lin SM. et al Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004; 127: 1714-1723
• 270 Bruix J. et al Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
• 271 Shiina S. et al A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130
• 272 Brunello F. et al Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-735
• 273 Lin SM. et al Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156
• 274 Shiina S. et al Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62 (Suppl. 01) 64-68
• 275 Hara K. et al Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology 2019; 69: 2533-2545
• 276 Peng ZW. et al Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-432
• 277 Liu H. et al Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103: 348-356
• 278 Endo K. et al Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53: 1575-1583
• 279 Fukutomi S. et al Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping. HPB (Oxford) 2017; 19: 1119-1125
• 280 Smolock AR. et al Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY) 2018; 43: 2497-2504
• 281 Bonomo G. et al Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session. Cardiovasc Intervent Radiol 2012; 35: 1372-1379
• 282 Lo CM. et al Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
• 283 Lammer J. et al Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52
• 284 Llovet JM. et al Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
• 285 Golfieri R. et al Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264
• 286 Yamada R. et al Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). J Gastrointest Oncol 2019; 10: 348-353
• 287 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1: Cd011313
• 288 Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 2018; 15: 299-310
• 289 Ludwig JM. et al Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017; 27: 2031-2041
• 290 Casadei Gardini A. et al Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321
• 291 Kolligs FT. et al Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015; 35: 1715-1721
• 292 Katsanos K. et al Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One 2017; 12: e0184597
• 293 Pitton MB. et al Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015; 38: 352-360
• 294 Lobo L. et al Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2016; 39: 1580-1588
• 295 Salem R. et al Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11: 1358-1365.e1
• 296 Sangro B. et al Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging 2018; 45: 1721-1730
• 297 Johnson GE. et al Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2016; 27: 1123-1129
• 298 Hilgard P. et al Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749
• 299 Sangro B. et al Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878
• 300 Kulik LM. et al Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81
• 301 Mazzaferro V. et al Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57: 1826-1837
• 302 Salem R. et al Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64
• 303 Rim CH. et al Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol 2018; 129: 112-122
• 304 Vogel A. et al Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv238-iv255
• 305 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019; 13: 227-299
• 306 Feng M. et al Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 2018; 4: 40-47
• 307 Kim JW. et al Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. Dig Liver Dis 2019; 51: 445-451
• 308 Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol 2018; 126: 527-533
• 309 Takeda A. et al Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 2016; 122: 2041-2049
• 310 Lasley FD. et al Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 2015; 5: e443-e449
• 311 Scorsetti M. et al The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015; 141: 1301-1309
• 312 Bujold A. et al Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31: 1631-1639
• 313 Méndez Romero A. et al Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006; 45: 831-837
• 314 Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol 2019; 131: 135-144
• 315 Lee J. et al Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol 2020; 145: 63-70
• 316 Rajyaguru DJ. et al Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol 2018; 36 (06) 600-608
• 317 Wahl DR. et al Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol 2016; 34 (05) 452-459
• 318 Sapir E. et al Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018; 100 (01) 122-130
• 319 Mohnike K. et al Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. Cardiovasc Intervent Radiol 2019; 42: 239-249
• 320 Collettini F. et al CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015; 191: 405-412
• 321 Mohnike K. et al Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179
• 322 Fukumitsu N. et al A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 74: 831-836
• 323 Bush DA. et al Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys 2016; 95: 477-482
• 324 Kim TH. et al Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 2015; 47: 34-45
• 325 Hong TS. et al Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 2016; 34: 460-468
• 326 Nakayama H. et al Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys 2011; 80: 992-995
• 327 Nakayama H. et al Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009; 115: 5499-5506
• 328 Mizumoto M. et al Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 2008; 71: 462-467
• 329 Sugahara S. et al Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 76: 460-466
• 330 Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY) 2018; 43: 101-110
• 331 Santillan C. et al LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY) 2018; 43: 75-81
• 332 Takahashi S. et al Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72 (Suppl. 01) 98-103
• 333 Guglielmi A. et al Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008; 103: 597-604
• 334 Yoon JH. et al Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 2010; 21: 348-356
• 335 Vauthey JN. et al Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12: 289-299
• 336 Schima W. et al Post-treatment imaging of liver tumours. Cancer Imaging 2007; 7: S28-S36
• 337 Frieser M. et al Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. Ultraschall in Med 2011; 32: 148-153
• 338 Schacherer D. et al Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma. Dig Dis 2009; 27: 109-113
• 339 Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008; 48: 848-857
• 340 Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33: 11-17
• 341 Tsai MC. et al Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2010; 25: 605-612
• 342 Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res 2013; 19: 1312-1314
• 343 Vincenzi B. et al Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015; 10: e0133488
• 344 Finn RS. et al Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905
• 345 Cheng AL. et al Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
• 346 Llovet JM. et al Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
• 347 Kudo M. et al Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018; 391: 1163-1173
• 348 Bruix J. et al Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017; 389: 56-66
• 349 Abou-Alfa GK. et al Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379: 54-63
• 350 Zhu AX. et al Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296
• 351 Llovet JM. et al Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
• 352 Zhu AX. et al Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2019; 20: 282-296
• 353 Cainap C. et al Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33: 172-179
• 354 Johnson PJ. et al Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524
• 355 Zhu AX. et al SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33: 559-566
• 356 Cheng AL. et al Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075
• 357 Bruix J. et al Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66
• 358 Reig M. et al Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 2013; 58: 2023-2031
• 359 El-Khoueiry AB. et al Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389: 2492-2502
• 360 Zhu AX. et al Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19: 940-952
• 361 Finn RS. et al Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38: 193-202
• 362 Marrero JA. et al Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65: 1140-1147
• 363 Ganten TM. et al Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. Clin Cancer Res 2017; 23: 5720-5728
• 364 Leal CRG. et al Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018; 36: 911-918
• 365 Pressiani T. et al Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24: 406-411
• 366 Ogasawara S. et al Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33: 729-739
• 367 Kambhampati S. et al Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer 2019; 125: 3234-3241
• 368 Vilgrain V. et al Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624-1636
• 369 Vilgrain V. et al Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. The Lancet Oncology 2017; 18: 1624-1636
• 370 Chow PKH. et al SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36: 1913-1921
• 371 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1: CD011313
• 372 Lencioni R. et al Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64: 1090-1098
• 373 Meyer T. et al Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565-575
• 374 Chow PKH. et al SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36: 1913-1921
• 375 Meyer T. et al Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology 2017; 2: 565-575
• 376 Ricke J. et al Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71: 1164-1174
• 377 Kudo M. et al Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69: 1492-1501
• 378 Kudo M. et al Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). Hepatol Res 2019; 49: 981-989
• 379 Kudo M. et al TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). Journal of Clinical Oncology 2021; 39 (Suppl. 03) 270
• 380 Bruix J. et al Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Oncology 2015; 16: 1344-1354
• 381 Katzenstein HM. et al Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol 2002; 20: 2789-2797
• 382 Czauderna P. et al Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20: 2798-2804
• 383 Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017; 4: 15-21
• 384 Schmid I. et al Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2012; 58: 539-544
• 385 Schütte K. et al Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr 2015; 34: 1122-1127
• 386 Huang TH. et al Malnutrition associated with an increased risk of postoperative complications following hepatectomy in patients with hepatocellular carcinoma. HPB (Oxford) 2019; 21: 1150-1155
• 387 Arends J. et al ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11-48
• 388 Ciuni R. et al Nutritional aspects in patient undergoing liver resection. Updates Surg 2011; 63: 249-252
• 389 Cederholm T. et al GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019; 10: 207-217
• 390 Fujiwara N. et al Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63: 131-140
• 391 Badran H. et al Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients. Asian Pac J Cancer Prev 2020; 21: 3285-3290
• 392 Kim N. et al Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 2020; 70: 1593-1603
• 393 Mardian Y. et al Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study. BMC Gastroenterol 2019; 19: 229
• 394 Voron T. et al Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2015; 261: 1173-1183
• 395 Plauth M. et al ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019; 38: 485-521
• 396 Haun MW. et al Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017; 6: CD011129
• 397 Adler K. et al [Integration of palliative care into intensive care: Systematic review]. Anaesthesist 2017; 66: 660-666
• 398 Dalgaard KM. et al Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome. Palliat Support Care 2014; 12: 495-513
• 399 Davis MP. et al A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 2015; 4: 99-121
• 400 Gaertner J. et al Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. BMJ 2017; 357: j2925
• 401 Hui D. et al Integration of oncology and palliative care: a systematic review. Oncologist 2015; 20: 77-83
• 402 Hui D. et al Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review. Oncologist 2016; 21: 895-901
• 403 Tassinari D. et al Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature. Rev Recent Clin Trials 2016; 11: 63-71
• 404 Hamano J. et al Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study. Oncologist 2015; 20: 839-844
• 405 Moroni M. et al The “surprise” question in advanced cancer patients: A prospective study among general practitioners. Palliat Med 2014; 28: 959-964
• 406 Murray S, Boyd K. Using the “surprise question” can identify people with advanced heart failure and COPD who would benefit from a palliative care approach. Palliat Med 2011; 25: 382
• 407 Moss AH. et al Prognostic significance of the “surprise” question in cancer patients. J Palliat Med 2010; 13: 837-840
• 408 European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
• 409 Kremer AE. et al Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008; 68: 2163-2182
• 410 Stander S. et al S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. J Dtsch Dermatol Ges 2017; 15: 860-873
• 411 Stander S. et al Pathogenesis of pruritus. J Dtsch Dermatol Ges 2011; 9: 456-463
• 412 Bachs L. et al Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1: 574-576
• 413 Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-493
• 414 Terg R. et al Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-722
• 415 Bergasa NV. et al A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-549
• 416 Mayo MJ. et al Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666-674
• 417 Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695
• 418 Talwalkar JA. et al Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1: 297-302
• 419 Zapata R. et al Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Int 2005; 25: 548-554
• 420 Lemyze M. et al Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation. Presse Med 2010; 39: e174-e181
• 421 Epstein SK. et al Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl 2004; 10: 418-424
• 422 van Ginneken BT. et al Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol 2007; 100: 345-353
• 423 van den Berg-Emons R. et al Fatigue is a major problem after liver transplantation. Liver Transpl 2006; 12: 928-933
• 424 van Ginneken BT. et al Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients. Disabil Rehabil 2010; 32: 2107-2112
• 425 Schwibbe G. [Changes in quality of life in oncological patients in the course of an inpatient after-care program]. Rehabilitation (Stuttg) 1991; 30: 55-62
• 426 Gärtner U. et al [Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation]. Med Klin (Munich) 1996; 91: 501-508
• 427 Fan SY. et al Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psychooncology 2013; 22: 1353-1360
• 428 Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol 2010; 8: 559-564.e1–e10
• 429 Qiao CX. et al Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18: 2689-2694
• 430 Steel JL. et al Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007; 25: 2397-2405
• 431 Lee HH. et al Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma. J Affect Disord 2019; 246: 361-367
• 432 Huang TW, Lin CC. The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma. Cancer Nurs 2009; 32: 398-403
• 433 Ahn MH. et al Suicide in cancer patients within the first year of diagnosis. Psychooncology 2015; 24: 601-607
• 434 Chiu CC. et al Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study. Asian Pac J Cancer Prev 2018; 19: 65-72
• 435 Shun SC. et al Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012; 17: 732-739
• 436 Shun SC. et al The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home. Cancer Nurs 2017; 40: 245-254
• 437 Wang ZX. et al Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia. World J Gastroenterol 2008; 14: 931-935
• 438 Sanson-Fisher R. et al The unmet supportive care needs of patients with cancer. Supportive Care Review Group. Cancer 2000; 88: 226-237
• 439 Kleeberg UR. et al Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 2005; 13: 303-310
• 440 Fallowfield L, Jenkins V. Communicating sad, bad, and difficult news in medicine. Lancet 2004; 363: 312-319
• 441 Ong LM. et al Doctor-patient communication and cancer patients’ quality of life and satisfaction. Patient Educ Couns 2000; 41: 145-156
• 442 de Haes H, Teunissen S. Communication in palliative care: a review of recent literature. Curr Opin Oncol 2005; 17: 345-350
• 443 Fukui S. et al A randomized study assessing the efficacy of communication skill training on patients’ psychologic distress and coping: nurses’ communication with patients just after being diagnosed with cancer. Cancer 2008; 113: 1462-1470
• 444 Razavi D. et al How to optimize physicians’ communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops. J Clin Oncol 2003; 21: 3141-3149
• 445 Lienard A. et al Factors that influence cancer patients’ and relatives’ anxiety following a three-person medical consultation: impact of a communication skills training program for physicians. Psychooncology 2008; 17: 488-496
• 446 Edwards A, Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. Health Expect 2006; 9: 307-320
• 447 Butow P. et al Shared decision making coding systems: how do they compare in the oncology context?. Patient Educ Couns 2010; 78: 261-268
• 448 Gordon EJ. et al Are informed consent forms for organ transplantation and donation too difficult to read?. Clin Transplant 2012; 26: 275-283
• 449 Volk ML. et al Patient decision making about organ quality in liver transplantation. Liver Transpl 2011; 17: 1387-1393
• 450 Rodrigue JR, Hanto DW, Curry MP. Patients’ expectations and success criteria for liver transplantation. Liver Transpl 2011; 17: 1309-1317
• 451 Butow PN, Tattersall MH, Goldstein D. Communication with cancer patients in culturally diverse societies. Ann N Y Acad Sci 1997; 809: 317-329
• 452 Dowsett SM. et al Communication styles in the cancer consultation: preferences for a patient-centred approach. Psychooncology 2000; 90: 147-156
• 453 Epstein RM. Making communication research matter: what do patients notice, what do patients want, and what do patients need?. Patient Educ Couns 2006; 60: 272-278
• 454 Zachariae R. et al Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer 2003; 88: 658-665
• 455 Strasser F. et al Impact of physician sitting versus standing during inpatient oncology consultations: patients’ preference and perception of compassion and duration. A randomized controlled trial. J Pain Symptom Manage 2005; 29: 489-497
• 456 Fogarty LA. et al Can 40 seconds of compassion reduce patient anxiety?. J Clin Oncol 1999; 17: 371-379
• 457 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF). Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1. 2017. Available from: http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/
• 458 Ashoori N. et al Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion 2012; 86: 338-348
• 459 Boteon A. et al The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study. Clin Transplant 2018; 32: e13255
• 460 Habibollahi P. et al Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study. J Vasc Interv Radiol 2019; 30: 323-329
• 461 Lu DS. et al Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137
• 462 Nicolini A. et al Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 327-332
• 463 Sandow T. et al Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. J Vasc Interv Radiol 2019; 30: 995-1003
• 464 Tan CHN. et al Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?. Ann Hepatobiliary Pancreat Surg 2018; 22: 27-35
• 465 Werner JD. et al Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2019; 17: 638-643
• 466 Wang JH. et al Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-418
• 467 Peng ZW. et al Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262: 1022-1033
• 468 Hasegawa K. et al Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724-729
• 469 Fang Y. et al Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 193-200
• 470 Miura JT. et al Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015; 17: 896-901
• 471 Zhang M. et al Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2017; 10: 4829-4839
• 472 Zhang QB. et al Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. Int J Hyperthermia 2017; 33: 255-262
• 473 Liu PH. et al Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2  cm in a Propensity Score Model. Ann Surg 2016; 263: 538-545
• 474 Takayasu K. et al Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int 2018; 38: 484-493
• 475 Hung HH. et al Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011; 9: 79-86
• 476 Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7: 214-221
• 477 Lü MD. et al [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2006; 86: 801-805
• 478 Lupo L. et al Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?. HPB (Oxford) 2007; 9: 429-434
• 479 Abu-Hilal M. et al Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008; 12: 1521-1526
• 480 Tashiro H. et al Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol 2011; 104: 3-9
• 481 Kim JW. et al Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol 2013; 14: 626-635
• 482 Tang C. et al Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore) 2016; 95: e3754
• 483 Bholee AK. et al Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol 2017; 19: 844-852
• 484 Pan T. et al Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study. J Cancer 2017; 8: 3506-3513
• 485 Zhang R. et al Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018; 24: 219-224
• 486 Lin DY. et al Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology 1988; 94: 453-456
• 487 Pelletier G. et al A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184
• 488 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261
• 489 Bruix J. et al Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-1583
• 490 Pelletier G. et al Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 129-134
• 491 Stefanini GF. et al Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995; 75: 2427-2434
• 492 Bronowicki JP. et al Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74: 16-24
• 493 Kim JH. et al Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29: 1291-1298
• 494 Herber S. et al Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30: 1156-1165
• 495 Chung GE. et al Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634
• 496 Georgiades CS. et al Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659
• 497 Okazaki M. et al Transcatheter arterial embolization for inoperable hepatocellular carcinoma. Jpn J Clin Radiol 1991; 36: 535-539
• 498 Sacco R. et al Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1545-1552
• 499 van Malenstein H. et al A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34: 368-376
• 500 Dhanasekaran R. et al Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480
• 501 Ferrer Puchol MD. et al [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011; 53: 246-253
• 502 Wiggermann P. et al Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 2011; 17: Cr189-Cr195
• 503 Song MJ. et al Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-1250
• 504 Megías Vericat JE. et al Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. Radiologia 2015; 57: 496-504
• 505 Kloeckner R. et al Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465
• 506 Facciorusso A. et al Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31: 645-653
• 507 Baur J. et al Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med 2016; 8: 69-74
• 508 Gao S. et al Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60: 813-820
• 509 Huang K. et al Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 920-925
• 510 Zhou X. et al Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Med 2014; 7: 3892-3903
• 511 Zou JH. et al Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 2016; 17: 510-517
• 512 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis 2016; 48: 571-577